Skip to main content

Panacea Life Sciences Holdings, Inc 8-K, filed Dec 28, 2020

Panacea Life Sciences Holdings, Inc. (PLSH)

8-K 2020-12-28 For: 2020-12-22
View Original
Added on April 06, 2026

About this 8-K

Panacea Life Sciences Holdings, Inc filed this 8-K on December 28, 2020, reporting on events of December 22, 2020.

Items reported

  • Item 5.02: Director or officer change, or executive pay

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 22, 2020

EXACTUS, INC.

(Exact name of the registrant as specified in its charter)

Nevada 000-55828 27-1085858
(State<br>or other jurisdiction of (Commission (IRS<br>Employer
of<br>incorporation) File<br>Number) Identification<br>No.)

80 NE 4th Avenue, Suite 28, Delray Beach, FL 33483

(Address of principle executive offices) (Zip code)

Registrant’s telephone number, including area code: (561) 455-4822

_____________________________________________________________________

(Former name or address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below):

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading symbol(s) Name of exchange on which registered
N/A N/A N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

SECTION 5 – CORPORATE GOVERNANCE AND MANAGEMENT

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of CertainOfficers; Compensatory Arrangements of Certain Officers

On December 22, 2020, Kenneth Puzder resigned from his position as our Chief Financial Officer, effective immediately.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf of the undersigned hereunto duly authorized.

EXACTUS,<br>INC.
Date:     <br>December 28, 2020 By: <br>/s/ Alvaro Daniel<br>Alberttis<br><br><br>Alvaro<br>Daniel Alberttis<br><br><br>Chief<br>Operating Officer